evident by the analysis of BLyS-defi cient mice displaying lower numbers of mature B cells and of BLyS transgenic mice developing severe B-cell hyperplasia. Although APRIL can trigger diff erent B-cell responses in vitro, including proliferation and survival of human and murine B cells, it is less critical than BLyS in B-cell maintenance as APRIL knockout and transgenic mice reveal no gross abnormalities in lymphoid homeo stasis [2] . In fact, APRIL was found to modulate specifi c B-cell responses such as IgA isotype switching, increased IgM secretion and B1 cell activity.
Meanwhile, BLyS is an established promoter of B-celltriggered autoimmmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, whereas the role of APRIL in these pathologies is rather controversial. Neutralizing BLyS with the mAb belimumab displayed a modest, although statistically signifi cant, therapeutic eff ect in systemic lupus erythematosus [3, 4] . But blocking both BLyS and APRIL with atacicept (TACI-Fc) was associated with a pronounced reduction of immunoglobulins, and occurrence of serious infections led to a premature termination of a phase II/III trial in lupus nephritis [5] . Th e combination of mycofenolate mofetil with atacicept may have contributed to the decrease of immunoglobulins. However, atacicept combined with another drug such as methotrexate in patients with rheumatoid arthritis was also associated with a signifi cant reduction of immunoglobulins (especially IgM). In this autoimmune disease, atacicept failed to demonstrate effi cacy on American College of Rheumatology 20 criteria [6] . In contrast, administration of belimumab showed a modest but signifi cant effi cacy using the same evaluation criteria in rheumatoid arthritis [7] .
Th ese fi ndings suggest distinct roles for BLyS and APRIL in lupus and other B-cell-mediated autoimmune diseases. Elevated serum levels are found for both cytokines in lupus patients, and for BLyS there is a consensus in the literature that this refl ects its diseasepromoting activity. Elevated APRIL serum levels, however, have been -depending on the respective studyeither positively or negatively correlated with disease features [8] . One possible explanation for this discrepancy
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To target or not to target APRIL in systemic lupus erythematosus: that is the question! could be diff erences in the patient cohorts analyzed. A recent study by Jacob and colleagues analyzed a murine lupus model in APRIL-defi cient mice and observed elevated numbers of splenocytes, increased autoantibody production and a tendency towards increased IgG production [9] . Notably, ectopic APRIL expression does not result -in contrast to BLyS transgenic mice -in lupus-like symptoms. In fact, we found that APRIL does dampen collagen-induced arthritis, the most common mouse model for human arthritis [10] .
Experimental mouse models for autoimmune diseases obviously cannot entirely mimic human diseases. Nevertheless, in vivo data are accumulating that do not support a disease-supporting role for APRIL in B-cell-mediated auto immunity. Th e study by Treamtrakanpon and colleagues is putting forward the need to better elucidate the role of APRIL in B-cell-driven diseases before concluding a therapeutic approach.
